In Reply Bleyer and Barnes are right to call attention to the need for further investigation on the association of cannabis legalization to opioid deaths—a critical area that must be researched. In their response to our recently published article,1 and an article by Wen and Hockenberry,2 Bleyer and Barnes compared an aggregated opioid death rate for 19 states and the District of Columbia that are identified as having some form of legalized cannabis with the rate in 24 states that have no such laws. In contrast to our results, and the existing body of literature, the authors found that by December 2016, the opioid death rate had increased by 52% in states with any form of legalized cannabis compared with states with no cannabis law.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Bradford AC, Abraham A, Bagwell Adams G. Opioid Death Rate Acceleration in Jurisdictions Legalizing Marijuana Use—Reply. JAMA Intern Med. 2018;178(9):1281–1282. doi:10.1001/jamainternmed.2018.3891
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: